ZMYND8 as a novel diagnostic and prognostic biomarker in Glioma

Abstract

Abstract Background: Glioma is the most common and lethal tumor and its classification depends mainly on molecular parameters such as IDH, ATRX. However, the further classification of glioma is still uncertain. The purpose of this study was to evaluate the status of ZMYND8 expression and its diagnosis and prognostic value in adult patients of glioma. Methods: We detected IDH1-R132H, ATRX and ZMYND8 expression by using immunohistochemistry in 104 glioma patients and retrospectively evaluated the data to find out the relationship between ZMYND8 and other clinical features in this study. Results: Our results showed high expression of ZMYND8 is strongly associated with high-grade glioma (P<0.001) and worse overall survival (P<0.05). ATRX loss is closely correlated with ZMYND8 (P<0.05). These patients were divided into three groups and the distribution of patients’ age was significantly different. Patients combined IDH1-132H mutation with ATRX loss had a longer overall survival. Multivariate cox regression analysis demonstrated that IDH1-132H was an independent indicator of OS and PFS in glioma, and ATRX was an independent indicator of OS, ZMYND8 was an independent indicator of PFS. Conclusion: The new model might help to predict the outcome of patients with glioma.